Last Updated on October 10, 2024 by The Health Master
The United States Food and Drug Administration (USFDA) has given tentative approval to Alembic Pharma’s Abbreviated New Drug Application (ANDA), acalabrutinib capsules, 100 mg, according to a statement from Alembic Pharma.
The statement said that the approved ANDA is therapeutically equivalent to the Reference Listed Drug (RLD) product, Calquence capsules, 100 mg, of AstraZeneca.
Acalabrutinib capsules are indicated for the treatment of adult patients with Mantle Cell Lymphoma (MCL) who have received at least one prior therapy and treatment of adult patients with Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL), the statement added.
USFDA gives tentative approval for Dolutegravir and Rilpivirine tablets
USFDA gives tentative approval for Levomilnacipran extended-release capsules
USFDA gives approval for Febuxostat tablets
USFDA gives approval for Prasugrel tablets
USFDA approves Fesoterodine Fumarate Extended-Release tablets
USFDA gives final approval for this Insomnia drug
NPPA revised Ceiling price of 111 scheduled formulations: January 2023
NABL asks laboratories to make fresh registrations in new NABL portal
Drug alert: 70 out of 1375 samples declared as NSQ in December 2022
USFDA gives tentative approval for Dolutegravir and Rilpivirine tablets
DCGI approves Covovax as booster dose
USFDA gives tentative approval for Levomilnacipran extended-release capsules
IPC includes dissolution test in IP: Read details
NPPA fixes retail price of 12 formulations: January 2023
NABL suspends accreditation of 80 laboratories
Latest Notifications regarding Pharmaceuticals
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos by The Health Master, click on the below YouTube icon:
For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos on consumer awareness, click on the below YouTube icon:
